Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer

Ronald de Wit; B Tombal; S Freedland

doi:10.1016/j.eururo.2020.10.016

Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer

Ronald de Wit, B Tombal, S Freedland

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.

Original language	English
Pages (from-to)	170-172
Number of pages	3
Journal	European Urology
Volume	79
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2020.10.016
Publication status	Published - Feb 2021

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2020.10.016

Cite this

@article{067b9792e258481b98c425cc9bdeaed7,

title = "Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer",

abstract = "The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.",

author = "{de Wit}, Ronald and B Tombal and S Freedland",

year = "2021",

month = feb,

doi = "10.1016/j.eururo.2020.10.016",

language = "English",

volume = "79",

pages = "170--172",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer

AU - de Wit, Ronald

AU - Tombal, B

AU - Freedland, S

PY - 2021/2

Y1 - 2021/2

N2 - The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.

AB - The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.

UR - http://www.scopus.com/inward/record.url?scp=85096368979&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.10.016

DO - 10.1016/j.eururo.2020.10.016

M3 - Article

C2 - 33218827

SN - 0302-2838

VL - 79

SP - 170

EP - 172

JO - European Urology

JF - European Urology

IS - 2

ER -

Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer

Abstract

Research programs

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this